Rallybio Corporation (RLYB)

NASDAQ: RLYB · Real-Time Price · USD

0.990

-0.010 (-1.00%)

Nov 7, 2024, 4:00 PM EST - Market closed

Rallybio Employees

Rallybio had 43 employees as of December 31, 2023. The number of employees increased by 2 or 4.88% compared to the previous year.

Employees

43

Change (1Y)

2

Growth (1Y)

4.88%

Revenue / Employee

$6,953

Profits / Employee

-$1,718,163

Market Cap

41.07M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	43	2	4.88%
Dec 31, 2022	41	6	17.14%
Dec 31, 2021	35	-	-

Related Stocks

Company Name	Employees
NeueHealth	1,252
LakeShore Biopharma	758
Apyx Medical	252
Achilles Therapeutics	215
IceCure Medical	77
DURECT	58
Passage Bio	58
Eyenovia	57

Employee Rankings

RLYB News

9 hours ago - Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire
9 days ago - Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire
5 weeks ago - Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - Business Wire
6 weeks ago - Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire
2 months ago - Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire
2 months ago - Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire
2 months ago - Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire
2 months ago - National Vision Releases 2023 Sustainability Report - Business Wire